0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T21:06:00Z
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Sat 19 Oct 24, 01:57 PMAbbott Laboratories (ABT): Strong Q2 Performance and Innovative Product Approvals
Fri 18 Oct 24, 07:26 PMWall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
Fri 18 Oct 24, 01:30 PMAbbott Laboratories Third Quarter 2024 Earnings: EPS Beats Expectations
Fri 18 Oct 24, 10:23 AM3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Fri 18 Oct 24, 09:10 AMAbbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
Thu 17 Oct 24, 06:42 PMQ3 2024 Abbott Laboratories Earnings Call
Thu 17 Oct 24, 05:21 AMAbbott Stock Gains on Q3 Earnings Beat, Margins Expand
Wed 16 Oct 24, 05:57 PMAbbott Laboratories Delivers Strong Q3 2024 Results, Raises Full-Year Guidance
Wed 16 Oct 24, 04:14 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8306.00M | 8211.00M | 4968.00M | 4077.00M | 2873.00M |
| Minority interest | - | - | 219.00M | 213.00M | 198.00M |
| Net income | 6933.00M | 7071.00M | 4495.00M | 3687.00M | 2368.00M |
| Selling general administrative | 11012.00M | 11324.00M | 9696.00M | 9765.00M | 9744.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 24511.00M | 24538.00M | 19605.00M | 18673.00M | 17872.00M |
| Reconciled depreciation | 2013.00M | 2047.00M | 3327.00M | 3014.00M | 3278.00M |
| Ebit | 8362.00M | 8425.00M | 5357.00M | 4532.00M | 3789.00M |
| Ebitda | 10696.00M | 10749.00M | 7592.00M | 6659.00M | 5967.00M |
| Depreciation and amortization | 2334.00M | 2324.00M | 2235.00M | 2127.00M | 2178.00M |
| Non operating income net other | 502.00M | 319.00M | 157.00M | 215.00M | 49.00M |
| Operating income | 8362.00M | 8425.00M | 5357.00M | 4532.00M | 3650.00M |
| Other operating expenses | 35291.00M | 34650.00M | 29251.00M | 27372.00M | 26928.00M |
| Interest expense | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M |
| Tax provision | 1373.00M | 1140.00M | 497.00M | 390.00M | 539.00M |
| Interest income | 377.00M | 491.00M | 492.00M | 94.00M | 105.00M |
| Net interest income | -375.00000M | -490.00000M | -500.00000M | -576.00000M | -721.00000M |
| Extraordinary items | - | 0.00000M | 24.00M | 86.00M | -96.00000M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1373.00M | 1140.00M | 497.00M | 390.00M | 539.00M |
| Total revenue | 43653.00M | 43075.00M | 34608.00M | 31904.00M | 30578.00M |
| Total operating expenses | 16149.00M | 16113.00M | 14248.00M | 14141.00M | 14222.00M |
| Cost of revenue | 19142.00M | 18537.00M | 15003.00M | 13231.00M | 12706.00M |
| Total other income expense net | -56.00000M | -214.00000M | -389.00000M | -455.00000M | -56.00000M |
| Discontinued operations | - | - | 24.00M | 24.00M | 34.00M |
| Net income from continuing ops | 6933.00M | 7071.00M | 4471.00M | 3687.00M | 2334.00M |
| Net income applicable to common shares | 6933.00M | 7071.00M | 4495.00M | 3687.00M | 2353.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 74438.00M | 75196.00M | 72548.00M | 67887.00M | 67173.00M |
| Intangible assets | 10454.00M | 12739.00M | 14784.00M | 17025.00M | 18942.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2663.00M | 2346.00M | 1867.00M | 1786.00M | 1568.00M |
| Total liab | 37533.00M | 39172.00M | 39545.00M | 36586.00M | 36451.00M |
| Total stockholder equity | 36686.00M | 35802.00M | 32784.00M | 31088.00M | 30524.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 8631.00M | 7943.00M | 7741.00M | 6133.00M | 5525.00M |
| Common stock | 24709.00M | 24470.00M | 24145.00M | 23853.00M | 23512.00M |
| Capital stock | 24709.00M | 24470.00M | 24145.00M | 23853.00M | 23512.00M |
| Retained earnings | 35257.00M | 31528.00M | 27627.00M | 25847.00M | 24560.00M |
| Other liab | 6579.00M | 7815.00M | 8209.00M | 8307.00M | 8080.00M |
| Good will | 22799.00M | 23231.00M | 23744.00M | 23195.00M | 23254.00M |
| Other assets | 4917.00M | 4059.00M | 2784.00M | 2443.00M | 2192.00M |
| Cash | 9882.00M | 9799.00M | 6838.00M | 3860.00M | 3844.00M |
| Cash and equivalents | 9882.00M | 9799.00M | 6838.00M | 3860.00M | 3844.00M |
| Total current liabilities | 15489.00M | 13105.00M | 11907.00M | 10863.00M | 9012.00M |
| Current deferred revenue | - | - | - | - | 305.00M |
| Net debt | 7834.00M | 9207.00M | 12811.00M | 15034.00M | 15722.00M |
| Short term debt | 2251.00M | 754.00M | 220.00M | 1478.00M | 207.00M |
| Short long term debt | 2251.00M | 754.00M | 220.00M | 1478.00M | 207.00M |
| Short long term debt total | 17716.00M | 19006.00M | 19649.00M | 18894.00M | 19566.00M |
| Other stockholder equity | -15229.00000M | -11822.00000M | -10042.00000M | -10147.00000M | -9962.00000M |
| Property plant equipment | 9162.00M | 8959.00M | 9029.00M | 8038.00M | 7563.00M |
| Total current assets | 25224.00M | 24239.00M | 20441.00M | 15667.00M | 14632.00M |
| Long term investments | 766.00M | 816.00M | 821.00M | 883.00M | 897.00M |
| Net tangible assets | 10955.00M | -2189.00000M | 3367.00M | -70.00000M | -11672.00000M |
| Short term investments | 288.00M | 450.00M | 310.00M | 280.00M | 242.00M |
| Net receivables | 8881.00M | 6487.00M | 6414.00M | 5425.00M | 5182.00M |
| Long term debt | 14522.00M | 17296.00M | 18527.00M | 16661.00M | 19359.00M |
| Inventory | 6173.00M | 5157.00M | 5012.00M | 4316.00M | 3796.00M |
| Accounts payable | 4607.00M | 4408.00M | 3946.00M | 3252.00M | 2975.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 219.00M | 222.00M | 219.00M | 213.00M | 198.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8051.00000M | -8374.00000M | -8946.00000M | -8465.00000M | -7586.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 24709.00M | 24470.00M | 24145.00M | 23853.00M | 23512.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 35257.00M | 31528.00M | 27627.00M | 25847.00M | 24560.00M |
| Treasury stock | - | -11822.00000M | -10042.00000M | -10147.00000M | -9962.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | 52220.00M | 17.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 49214.00M | 50957.00M | 52107.00M | 52220.00M | 52541.00M |
| Capital lease obligations | 943.00M | 956.00M | 902.00M | 755.00M | - |
| Long term debt total | 14522.00M | 17296.00M | 18527.00M | 16661.00M | 19359.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -33.00000M | -96.00000M | -73.00000M | -82.00000M | -58.00000M |
| Change to liabilities | 37.00M | 380.00M | 1152.00M | -325.00000M | 533.00M |
| Total cashflows from investing activities | -1740.00000M | -2008.00000M | -2215.00000M | -1815.00000M | -1356.00000M |
| Net borrowings | 47.00M | -248.00000M | -50.00000M | -1599.00000M | -8450.00000M |
| Total cash from financing activities | -7636.00000M | -5494.00000M | -2779.00000M | -4289.00000M | -10391.00000M |
| Change to operating activities | -75.00000M | -312.00000M | -627.00000M | -138.00000M | 23.00M |
| Net income | 6933.00M | 7071.00M | 4495.00M | 3687.00M | 2368.00M |
| Change in cash | 83.00M | 2961.00M | 2978.00M | 16.00M | -5563.00000M |
| Begin period cash flow | 9799.00M | 6838.00M | 3860.00M | 3844.00M | 9407.00M |
| End period cash flow | 9882.00M | 9799.00M | 6838.00M | 3860.00M | 3844.00M |
| Total cash from operating activities | 9581.00M | 10533.00M | 7901.00M | 6136.00M | 6300.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 3267.00M | 3538.00M | 3327.00M | 3014.00M | 3278.00M |
| Other cashflows from investing activities | 70.00M | -27.00000M | 35.00M | -95.00000M | 96.00M |
| Dividends paid | -3309.00000M | -3202.00000M | -2560.00000M | -2270.00000M | 1974.00M |
| Change to inventory | -1413.00000M | -456.00000M | -493.00000M | -593.00000M | -514.00000M |
| Change to account receivables | -68.00000M | -383.00000M | -924.00000M | -275.00000M | -190.00000M |
| Sale purchase of stock | -3795.00000M | -2299.00000M | -403.00000M | -718.00000M | -238.00000M |
| Other cashflows from financing activities | 221.00M | 55.00M | -11.00000M | 2140.00M | 4254.00M |
| Change to netincome | 685.00M | 640.00M | 546.00M | 582.00M | 644.00M |
| Capital expenditures | 1777.00M | 1885.00M | 2177.00M | 1638.00M | 1394.00M |
| Change receivables | -68.00000M | -383.00000M | -924.00000M | -275.00000M | -190.00000M |
| Cash flows other operating | 140.00M | -257.00000M | -202.00000M | 46.00M | 181.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 205.00M | 3031.00M | 2907.00M | 32.00M | -5447.00000M |
| Change in working capital | -1519.00000M | -771.00000M | -892.00000M | -1331.00000M | -148.00000M |
| Stock based compensation | 685.00M | 640.00M | 546.00M | 519.00M | 477.00M |
| Other non cash items | 215.00M | 55.00M | 425.00M | 247.00M | 32.00M |
| Free cash flow | 7804.00M | 8648.00M | 5724.00M | 4498.00M | 4906.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories |
1.33 1.15% | 117.26 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
4.08 1.06% | 389.76 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.62 0.74% | 84.73 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.38 1.53% | 91.55 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
| SEMHF Siemens Healthineers AG |
- -% | 51.20 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert B. Ford | Chairman, Pres & CEO | 1974 |
| Mr. Robert E. Funck Jr. | Exec. VP of Fin. & CFO | 1961 |
| Mr. Hubert L. Allen | Exec. VP, Gen. Counsel & Sec. | 1966 |
| Mr. Daniel Gesua Sive Salvadori | Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products | 1979 |
| Ms. Andrea F. Wainer | Exec. VP of Rapid & Molecular Diagnostics | 1970 |
| Mr. Scott Michael Leinenweber | VP of Investor Relations, Licensing & Acquisitions | 1972 |
| James E. Young | VP and Chief Ethics & Compliance Officer | NA |
| Ms. Melissa Brotz | VP of Public Affairs & Corp. Marketing | NA |
| Ms. Elaine R. Leavenworth | Sr. VP and Chief Marketing & External Affairs Officer | 1959 |
| Ms. Mary K. Moreland | Exec. VP of HR | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...